A new­ly pri­vate No­var­tis part­ner bags a megaround on its first go to tur­bocharge CAR-T, cell ther­a­py pipeline

An ear­ly fore­run­ner of Chi­nese biotech’s grow­ing in­flu­ence glob­al­ly, Cel­lu­lar Bio­med­i­cine — or CB­MG – ap­peared to be tak­ing two steps back­ward when it delist­ed on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER